Please login to the form below

Not currently logged in
Email:
Password:

Alkopharma acquires rights to Navoban

Novartis has closed a deal to sell its antiemetic drug, Navoban, to fellow Swiss company, Alkopharma, giving Alkopharma worldwide rights.

Novartis has closed a deal to sell its antiemetic drug, Navoban, to fellow Swiss company, Alkopharma, giving Alkopharma worldwide rights. 

Alkopharma intends to commercialise the drug in more than 80 countries and will drive into new markets, such as the US, to reinforce the company's growing position globally.

Alain Bouaziz, Alkopharma's president and CEO, said the deal marked an exciting step for the company and maintained the ethical basis that the company was founded on 10 years ago.

Alkopharma acquires original molecules from large pharmaceutical companies that are no longer interested in manufacturing drugs from them, such as those used in orphan diseases. In this way, it attempts to meet patients' needs for personalised treatments for rare diseases.

A new manufacturing facility is to be built in Wallis, Switzerland, starting in January 2010, to support the company's R&D and expansion plans. It will house two units, one dedicated to the production of anti-tumour products and the other to biotech-derived products.

11th November 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics